{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:52:31Z","timestamp":1790661151373,"version":"4.1.0"},"reference-count":173,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016238","name":"Ministry of Economic Affairs and Climate Policy","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016238","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.1080\/14728214.2024.2336986","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T03:36:05Z","timestamp":1712201765000},"page":"305-320","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3345-9785","authenticated-orcid":false,"given":"Willemien F.J.","family":"Hof","sequence":"first","affiliation":[{"name":"University Medical Center Groningen","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-3291","authenticated-orcid":false,"given":"Jan Freark","family":"de Boer","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen","place":["Groningen, The Netherlands"]},{"name":"University Medical Center Groningen","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-2861","authenticated-orcid":false,"given":"Henkjan J.","family":"Verkade","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14553"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2015.04.003"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-1"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)61408-2"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2647"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00476.2020"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_231"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.09.019"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500457200"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2210-7401(12)70018-9"},{"key":"e_1_3_5_13_1","unstructured":"Johns Hopkins University. Online Mendelian inheritance in man PFIC [Internet]. 2023. Available from: https:\/\/www.omim.org\/search?index=entry&start=1&limit=10&sort=score+desc%2C+prefix_sort+desc&search=pfic"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23539"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.07.042"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.038"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318212ec87"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3247"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.025"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.23984"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119799"},{"issue":"1","key":"e_1_3_5_22_1","first-page":"A159","article-title":"Reduced expression of TJP-2 is associated with chronic liver disease and hepatic malignancy","volume":"65","author":"Kamarajah S","year":"2016","unstructured":"Kamarajah S, Patten D, Wadkin J, et al. Reduced expression of TJP-2 is associated with chronic liver disease and hepatic malignancy. Gut. 2016;65(1):A159.","journal-title":"Gut"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2015.1026537"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2918"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.01.027"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10713"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29020"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i47.7470"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.015"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28779"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030481"},{"issue":"11","key":"e_1_3_5_32_1","first-page":"1","article-title":"A novel homozygous mutation in the MYO5B gene associated with normal-gamma-glutamyl transferase progressive familial intrahepatic cholestasis","volume":"13","author":"Uyar Aksu N","year":"2021","unstructured":"Uyar Aksu N, G\u00f6r\u00fckmez O, \u00d6 G\u00f6r\u00fckmez, et al. A novel homozygous mutation in the MYO5B gene associated with normal-gamma-glutamyl transferase progressive familial intrahepatic cholestasis. Cureus. 2021;13(11):1\u20135.","journal-title":"Cureus"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002926"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.10.001"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.18.9654"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.09.019"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106706"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01775-8"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-020-00706-2"},{"key":"e_1_3_5_40_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2023.1061535","article-title":"Case Report: add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis","volume":"11","author":"Pepe A","year":"2023","unstructured":"Pepe A, Colucci A, Carucci M, et al. Case Report: add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis. Front Pediatr. 2023;11(February):1\u20135.","journal-title":"Front Pediatr"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03279-w"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00723-3"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.026187"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2013.10.005"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.04.013"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M808667200"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sempedsurg.2020.150946"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70287-8"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.007"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181596060"},{"issue":"1","key":"e_1_3_5_51_1","first-page":"1","article-title":"Gene therapy for progressive familial intrahepatic cholestasis: current progress and future prospects","volume":"22","author":"Bosma PJ","year":"2021","unstructured":"Bosma PJ, Wits M, Oude-Elferink RPJ. Gene therapy for progressive familial intrahepatic cholestasis: current progress and future prospects. Int J Mol Sci. 2021;22(1):1\u201313.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2018.06.003"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061238"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26974"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.04.077"},{"issue":"3","key":"e_1_3_5_56_1","first-page":"216","article-title":"Progressive familial intrahepatic cholestasis in Malaysian patients - A report of five cases","volume":"64","author":"Lee WS","year":"2009","unstructured":"Lee WS, Chai PF, Looi LM. Progressive familial intrahepatic cholestasis in Malaysian patients - A report of five cases. Med J Malaysia. 2009;64(3):216\u2013219.","journal-title":"Med J Malaysia"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2011.08.010"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31819a4e3d"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01884-4"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v6.i2.278"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000282869.94152.4f"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2018.07.010"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8457-4"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01594-y"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-19033"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306896"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.11.012"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.10.018"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.009"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199402000-00003"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/295891"},{"issue":"4","key":"e_1_3_5_73_1","first-page":"351","article-title":"Drug treatment of pruritus in liver diseases","volume":"15","author":"Hegade VS","year":"2015","unstructured":"Hegade VS, Kendrick SFW, Jones DEJ. Drug treatment of pruritus in liver diseases. Clin Med J R Coll Physicians London. 2015;15(4):351\u2013357.","journal-title":"Clin Med J R Coll Physicians London"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-011-0653-0"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00258.2004"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00687-7"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80268-6"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.009"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002801"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu9101127"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2016.05.003"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90301-0"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2015.08.011"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2019.09.018"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2008.00878.x"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29019"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/children10060949"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i5.763"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000092"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1168"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-43570"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1714657"},{"issue":"5","key":"e_1_3_5_93_1","first-page":"767","article-title":"Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation","volume":"13","author":"Miyagawa-Hayashino A","year":"2007","unstructured":"Miyagawa-Hayashino A, Egawa H, Yorifuji T, et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transplant. 2007;13(5):767\u2013768.","journal-title":"Liver Transplant"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22074"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2007.00722.x"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01514.x"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12782"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21287"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.004"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901075"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23083"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28311"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000238"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i18.4438"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13457"},{"key":"e_1_3_5_106_1","unstructured":"European Medicines Agency. Bylvay (odevixibat) medicine overview [Internet]. 2021 cited 2023 Oct 24. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mylotarg-epar-summary-public_en.pdf"},{"key":"e_1_3_5_107_1","unstructured":"Albireo Pharma. Bylvay Prescribing Information [Internet]. 2023 cited 2023 Oct 24. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215498s000lbl.pdf"},{"key":"e_1_3_5_108_1","unstructured":"European Medicines Agency. Bylvay Summary of Product Characteristics [Internet]. 2021 cited 2023 Oct 24. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bylvay-epar-product-information_en.pdf"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00093-0"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i29.5295"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100782"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01256-3"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100573"},{"key":"e_1_3_5_114_1","unstructured":"Food & Drug Administration. Orphan drug designations and approvals [Internet]. 2021. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=370912"},{"key":"e_1_3_5_115_1","unstructured":"European Medicines Agency. Orphan maintenance assessment report bylvay (Odevixibat) [Internet]. 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi"},{"key":"e_1_3_5_116_1","unstructured":"Ipsen. The acquisition of Albireo [Internet]. 2023. Available from: https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/01\/23204433\/The-acquistion-of-Albireo.pdf"},{"key":"e_1_3_5_117_1","unstructured":"Committee for medicinal products for human use. Assessment report - Bylvay (Odevixibat). EMA\/319560\/2021. 2021."},{"key":"e_1_3_5_118_1","unstructured":"Albireo Pharma. Current report exhibit 99.2 [Internet]. 2020. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1322505\/000110465920008111\/tm205897d2_ex99-2.htm"},{"issue":"2","key":"e_1_3_5_119_1","article-title":"Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency","volume":"5","author":"Felzen A","year":"2023","unstructured":"Felzen A, van Wessel DBE, Gonzales E, et al. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency. JHEP Rep. 2023;5(2).","journal-title":"JHEP Rep"},{"key":"e_1_3_5_120_1","unstructured":"Albireo Pharma. Albireo reports Q3 2022 financial results and business update. 2022."},{"key":"e_1_3_5_121_1","unstructured":"Ipsen. Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance. YTD 2023 - sales announcement. 2023."},{"key":"e_1_3_5_122_1","unstructured":"Ipsen. U.S. FDA approves Bylvay\u00ae for patients living with cholestatic pruritus due to Alagille syndrome. 2023."},{"key":"e_1_3_5_123_1","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). TLV decision bylvay. 2023."},{"key":"e_1_3_5_124_1","unstructured":"Zorginstituut Nederland. GVS advice odevixibat (Bylvay\u00ae). 2023."},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00308.2020"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810758"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2012.05.004"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082033"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.012"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbiopara.2020.111313"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21630"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14518"},{"key":"e_1_3_5_133_1","unstructured":"European Medicines Agency. Livmarli summary of product characteristics [Internet]. 2022 cited 2023 Oct 26. Available from 2023 Oct 26: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/livmarli-epar-product-information_en.pdf"},{"key":"e_1_3_5_134_1","unstructured":"Food & Drug Administration. Livmarli Prescribing Information [Internet]. 2024 cited 2024 May 7. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214662s005s008lbl.pdf"},{"key":"e_1_3_5_135_1","unstructured":"Mirum Pharma. Mirum submits for European approval of LIVMARLI in progressive familial intrahepatic cholestasis [Internet]. Available from: https:\/\/ir.mirumpharma.com\/news-events\/News\/news-details\/2023\/Mirum-Submits-for-European-Approval-of-LIVMARLI-in-Progressive-Familial-Intrahepatic-Cholestasis\/default.aspx"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01649-0"},{"key":"e_1_3_5_137_1","unstructured":"Mirum Pharma. Mirum Pharmaceuticals announces data from EMBARK phase 2b study for biliary atresia. Available from: https:\/\/ir.mirumpharma.com\/news-events\/News\/news-details\/2023\/Mirum-Pharmaceuticals-Announces-Data-from-EMBARK-Phase-2b-Study-for-Biliary-Atresia\/default.aspx"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1980"},{"key":"e_1_3_5_139_1","volume-title":"Journal of pediatric gastroenterology and nutrition","author":"Miethke A","year":"2023","unstructured":"Miethke A, Moukarzel A, Porta G, et al. Efficacy and safety of maralixibat in patients with progressive familial intrahepatic cholestasis (march-pfic): a randomized placebo-controlled phase 3 study. In: Journal of pediatric gastroenterology and nutrition. 2023. p. 709\u2010710."},{"key":"e_1_3_5_140_1","unstructured":"A study to evaluate the efficacy and safety of maralixibat in subjects with progressive familial intrahepatic cholestasis (MARCH-PFIC) NCT03905330 [Internet]. 2023 cited 2023 Dec 8]. Available from 2023 Dec 8: https:\/\/clinicaltrials.gov\/study\/NCT03905330"},{"key":"e_1_3_5_141_1","article-title":"Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC","author":"Miethke A","year":"2023","unstructured":"Miethke A, Moukarzel A, Porta G, et al. Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC. J Hepatol. 2023;78:S387\u20138.","journal-title":"J Hepatol"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)01010-3"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)00526-3"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)00615-3"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53628-x"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00327.2007"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25591"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.04.017"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27767"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.12.032"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02125-4"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000376"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30509"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.033"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1209"},{"key":"e_1_3_5_156_1","unstructured":"Food & Drug Administration. OCALIVA\u00ae (obeticholic acid) Prescribing Information [Internet]. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207999s008lbl.pdf"},{"key":"e_1_3_5_157_1","unstructured":"European Medicines Agency. Ocaliva summary of product characteristics [Internet]. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocaliva-epar-product-information_en.pdf"},{"issue":"17","key":"e_1_3_5_158_1","first-page":"15","article-title":"6r-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari R","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, et al. 6r-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. Society. 2002;45(17):15\u201318.","journal-title":"Society"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100917"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102185"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2013.05.001"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250303"},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2012.03.016"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009098"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1159\/000454904"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.60"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)02982-3"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002713"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.88"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.021"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20222"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00008-08"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2024.2336986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:43:26Z","timestamp":1738543406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2024.2336986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":173,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["10.1080\/14728214.2024.2336986"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2024.2336986","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}